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There are seven members of the APOBEC3 family in humans (APOBEC3A through APOBEC3H) that have
antiviral activity against retroviruses and/or retroelements. To determine whether variants in APOBEC3
genes in human populations have altered antiviral activity, we identiﬁed and functionally tested novel
single nucleotide variants (SNVs) in APOBEC3 genes present in the 1000 Genome Project dataset. We
found that common variants minor allele frequency (41%) of APOBEC3A, C, F, and G do not affect protein
function. However, we found that two common novel polymorphisms in APOBEC3D decrease antiviral
activity against HIV-1, and one polymorphism decreases activity against Alu retrotransposons.
We characterized the diversity of APOBEC3 genes in three human populations and ﬁnd signiﬁcant
evidence that APOBEC3D has evolved under purifying selection in recent human history. These data
suggest that the activity of APOBEC3D has been maintained in human populations for a cellular function
in host defense.
& 2013 Elsevier Inc. All rights reserved.Introduction
The APOBEC3 family of retroviral restriction factors contains
seven paralogs in humans (APOBEC3A through APOBEC3H)
(Jarmuz et al., 2002; OhAinle et al., 2006). APOBEC3s are cytidine
deaminases that inhibit the replication of a diverse array of viruses
and retrotransposons (Chen et al., 2006; Esnault et al., 2005;
Mangeat et al., 2003; Okeoma et al., 2007; Sheehy et al., 2002;
Turelli et al., 2004). Most APOBEC3 proteins are constitutively
expressed in viral target cells, though some APOBEC3 proteins are
induced by interferon (Koning et al., 2009; Refsland et al., 2010).
APOBECSs inhibit viral replication during reverse transcription by
inducing hypermutation of viral genomes and by deamination-
independent methods (Harris et al., 2003; Macmillan et al., 2013;
Newman et al., 2005; Zhang et al., 2003).
Most lentiviral genomes contain an antagonist of APOBEC3s,
which is encoded by the vif gene in HIV-1, to overcome the
restriction imposed by APOBEC3s (Mariani et al., 2003; Sheehy
et al., 2003). This has led to an evolutionary ‘arms race’ between
hosts and viruses that has left a signature of positive selection, or
rapid evolution, in host and viral genes (Compton and Emerman,ll rights reserved.
rch Center, Mailstop C2-023,
ax: +1 206 667 6523.
an).2013). Many APOBEC3 genes, including APOBEC3G, APOBEC3H,
and APOBEC3D, which was called “APOBEC3DE” in earlier papers,
have evolved under positive selection for millions of years in
primates (Duggal et al., 2011; OhAinle et al., 2008; Sawyer et al.,
2004). At least one APOBEC3 gene within an Old World monkey
species has acquired population-speciﬁc polymorphisms in recent
history that allow host evasion from lentiviral infection (Compton
et al., 2012), suggesting that APOBEC3s may have rapidly evolved
in recent primate history as well.
Within humans, several APOBEC3s are known to have common
polymorphisms that render them defective. For example, two variants
of APOBEC3H have decreased protein expression (OhAinle et al.,
2008), and deletions of APOBEC3B are common in some human
populations (Kidd et al., 2007). Polymorphisms in APOBEC3F and
APOBEC3G have also been described (An et al., 2004; Mulder et al.,
2010; Reddy et al., 2010). However, whether variants that have
functional consequences are present in other APOBEC3 genes is
unknown. Moreover, the only allele of the human APOBEC3D gene
that has been functionally tested for antiviral activity is less active
against lentiviruses than the orthologous chimpanzee APOBEC3D
gene (Duggal et al., 2011). Because of widespread interest in under-
standing the contributions of human genetics to viral susceptibility
and disease, we sought to comprehensively identify and functionally
characterize variants of APOBEC3 genes in human populations.
Using the 1000 Genome Project dataset, we identify 21 amino acid-
altering mutations in the APOBEC3 locus, of which nine are reported
N.K. Duggal et al. / Virology 443 (2013) 329–337330for the ﬁrst time. We ﬁnd that six common (minor allele frequency,
MAF41%) single nucleotide variants (SNVs) in APOBEC3A, C, F, and G
have no effect on antiviral activity. However, two SNVs in APOBEC3D
decrease antiviral activity against HIV-1, and one of these two has
decreased activity against Alu retrotransposons. To better understand
the evolutionary pressures acting on the APOBEC3 locus, we perform
neutrality tests and ﬁnd that APOBEC3D is subject to purifying
selection in humans. These results highlight the conserved role of
APOBEC3D in host defense and suggest that APOBEC3D variants may
be only slightly deleterious.Results
Common polymorphisms in the APOBEC3 locus
To identify single nucleotide variants in the APOBEC3 locus, we
accessed the 1000 Genome Project Phase I genotypes for the
coding regions of each APOBEC3 gene, which consists of genotypes
from 913 geographically diverse individuals of African, Asian, and
European ancestries. We also obtained insertions and deletions for
911 of the same individuals from the 1000 Genome Project
Integrated Phase 1 release. A summary of the most common
(MAF41%) codon-altering variants found in APOBEC3A through
H is found in Table 1 and the SNVs functionally tested in this study
in Fig. 1.
The 1000 Genome Project dataset contains 12 previously
reported common variants in the APOBEC3 locus, including the
deletion of APOBEC3B (Kidd et al., 2007), the deletion of residue 15
in APOBEC3H (OhAinle et al., 2008), and SNVs in APOBEC3F
(A108S, V231I, Y307C) (Mulder et al., 2010), APOBEC3G (H186R,
Q275E) (An et al., 2004; Reddy et al., 2010), and APOBEC3H (R18L,
R105G, E121K/D, D178E) (OhAinle et al., 2008). These polymorph-
isms were previously identiﬁed using smaller datasets because of
their very high frequency. In addition to these previously reported
variants, nine additional common variants can also be found in
this dataset, including SNVs in APOBEC3A (T19A), APOBEC3B
(K62E, P98L, T146K, L189P, A254V), APOBEC3C (S188I), and APO-
BEC3D (R97C, R248K) (Fig. 1 and Table 1). Using the 1000 Genome
Project data, we have now identiﬁed all common polymorphisms
in the APOBEC3 locus by eliminating an ascertainment bias.
Consistent with previous reports of APOBEC3 variants in HapMap
populations, the deletion of APOBEC3B, the polymorphisms in
APOBEC3F at codons 108 and 231, and the polymorphisms in
APOBEC3H at codons 15, 105, 121, and 178 are found at their highest
frequencies in populations with Asian or European ancestries (Fig. 1).
In contrast, SNVs in APOBEC3A, APOBEC3C, APOBEC3D, and APO-
BEC3G are found at their highest frequencies in populations of
African ancestry. Thus, all APOBEC3 paralogs contain at least one
common non-synonymous polymorphism in a human population.
In addition, most variants in the APOBEC3 locus have population-APOBEC
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Fig. 1. Variants in the APOBEC3 locus tested in this study. The human APOBEC3 locus wit
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Common polymorphisms in APOBEC3A, C, F, and G do not affect
antiviral activity
All common variants in APOBEC3H have been well described
functionally in previous studies: the deletion of residue 15
decreases protein stability; the R105G mutation decreases protein
stability, alters cellular localization, and reduces RNA binding; the
D121K mutation decreases sensitivity to HIV-1 Vif; and the R18L
and D178E mutations have no effect on protein function (Harari
et al., 2009; Li et al., 2010; OhAinle et al., 2008; Tan et al., 2009;
Wang et al., 2011; Zhen et al., 2012, 2010). The loss of APOBEC3B in
many individuals suggests that APOBEC3B is not essential for
human health, and the insensitivity of APOBEC3B to HIV-1 Vif
(Doehle et al., 2005) suggests it is not relevant to HIV-1 infection.
Therefore, for the rest of our functional analyses of SNVs in
APOBEC3 genes, we focused on those found in APOBEC3A, C, D, F,
and G.
Human APOBEC3A and APOBEC3C inhibit the replication of
LINE-1 (Bogerd et al., 2006; Muckenfuss et al., 2006), with the
activity of APOBEC3A more potent than APOBEC3C. APOBEC3A
T19A and APOBEC3C S1881 mutations are present at frequencies
near 10% in African populations and o1% in other populations
(Table 1). As no SNVs in either paralog have been previously
described, we tested whether these APOBEC3A or APOBEC3C
variants affect their activity against a retroelement, LINE-1. Each
of these mutations was introduced into a plasmid containing
epitope-tagged APOBEC3A or APOBEC3C. We co-transfected
increasing amounts of APOBEC3 plasmids with a plasmid contain-
ing the non-LTR human retrotransposon LINE-1, which expresses
neomycin resistance after retrotransposition. Because APOBEC3A
is a stronger inhibitor of LINE-1 (Niewiadomska et al., 2007), we
used 10 times less APOBEC3A plasmid DNA compared to APO-
BEC3C in these assays. After selection in G418, neomycin-resistant
colonies were counted as a measure of LINE-1 activity. Although
APOBEC3A T19A and APOBEC3C S188I had slightly decreased
protein expression compared to wild-type APOBEC3A or APO-
BEC3C (Fig. 2A and B, upper panels), these polymorphisms did not
affect the ability of APOBEC3A or APOBEC3C to restrict the activity
of LINE-1 in a dose-dependent manner (Fig. 2A and B, lower
panels). These data suggest that the SNVs in APOBEC3A and
APOBEC3C do not alter their capacity to restrict LINE-1.
Human APOBEC3F has potent antiviral activity against HIV-
1Δvif and is sensitive to HIV-1 Vif (Bishop et al., 2004; Liddament
et al., 2004; Wiegand et al., 2004; Zheng et al., 2004), but reports
vary in its ability to inhibit LINE-1 (Bogerd et al., 2006; Hulme
et al., 2007; Stenglein and Harris, 2006). In this dataset, APOBEC3F
Y307C is present at a low frequency in African and European
populations (MAFo5%) and is absent in Asian populations.3 locus 
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Table 1
Derived allele frequency of common variants in APOBEC3 genes.
APOBEC3 Variant ID African (na¼246) Asian (n¼286) European (n¼381) Combined (n¼913) Citation
A T19A rs17000556 10.6 0 0.1 2.9
B K62E rs2076109 68.1 63.6 62.2 64.2
B P98L rs59708943 16.3 0 5.4 6.6
B T146K rs5995649 5.9 2.1 3.9 3.9
B L189P rs146055882 10.6 0 0 2.8
B A254V rs138093253 5.7 0 0.9 1.9
B CNVb CNV_36030 6.1 31.1 7.8c 14.6d Kidd et al. (2007)
C S188I rs112120857 9.6 0 0 2.6
D R97C rs75858538 4.7 0 0 1.3
D R248K rs61748819 11.6 0 0 3.1
F A108S rs2020390 30.1 70.8 47.2 50.0 Mulder et al. (2010)
F V231I rs2076101 20.1 70.8 47.2 47.3 Mulder et al. (2010)
F Y307C rs12157816 3.7 0 1.1 1.4 Mulder et al. (2010)
G H186R rs8177832 37.4 7.9 3.3 13.9 An et al. (2004)
G E275Q rs17496046 14.6 1.9 4.3 6.4 Reddy et al. (2010)
H R18L rs139293 6.1 16.1 31.1 19.7 OhAinle et al. (2008)
H R105G rs139297 15.9 67.7 52.2 47.3 OhAinle et al. (2008)
H E121K rs139298 13.8 68.0 51.8 46.7 OhAinle et al. (2008)
H E121D rs139299 86.8 32.3 48.4 53.7 OhAinle et al. (2008)
H E178D rs139302 15.4 67.5 52.2 47.1 OhAinle et al. (2008)
H Dele 15 rs59165009 33.1 24.8 35.2c 31.3d OhAinle et al. (2008)
a n¼Number of individuals.
b CNV¼Copy number variant.
c n¼379.
d n¼911.
e Del¼Deletion.
N.K. Duggal et al. / Virology 443 (2013) 329–337 331Previous reports have shown that APOBEC3F Y307C has reduced
antiviral activity (Dang et al., 2011) and increased sensitivity to
HIV-1 Vif (Mulder et al., 2010). In addition, APOBEC3F A108S and
V231I are present at intermediate to high frequencies (MAF 20–
70%) in all human populations, with the highest frequencies found
in individuals outside of Africa. We hypothesized that these high
frequency variants of APOBEC3F may explain the discrepancy in
reported anti-LINE activity. Therefore, we tested these two SNVs in
APOBEC3F for antiviral activity. As these two polymorphisms are
in strong linkage disequilibrium (LD) in all populations (r2¼0.91),
we introduced the mutations into the same APOBEC3F plasmid
and functionally assayed them together. Plasmids containing
APOBEC3F were co-transfected at multiple concentrations with
HIV-1 proviral constructs containing a luciferase gene and VSV-G
to produce pseudotyped virions. Equivalent amounts of virions
were used to infect SupT1 cells, and viral infectivity was deter-
mined by luciferase activity of infected cells. While these muta-
tions slightly increased protein expression of transfected
APOBEC3F (Fig. 2C, upper panel), they did not alter the ability of
APOBEC3F to restrict HIV-1Δvif (Fig. 2C, lower panel, solid lines) or
HIV-2Δvif (data not shown), and they did not alter their sensitivity
to degradation by HIV-1 Vif (Fig. 2C, lower panel, dashed lines) or
HIV-2 Vif (data not shown). We next asked if wild-type or mutant
APOBEC3F could inhibit LINE-1 retrotransposition. However,
neither wild-type nor mutant APOBEC3F restricted LINE-1 by
more than 3-fold, even at the highest concentration (Fig. 2C,
middle panel). From these data, we conclude that APOBEC3F does
not inhibit LINE-1 and that the common SNVs in APOBEC3F do not
alter its anti-HIV activity.
Human APOBEC3G has the most potent antiviral activity
against HIV-1Δvif, is highly sensitive to HIV-1 Vif (Refsland et al.,
2012), and restricts Alu elements (Esnault et al., 2005; Hulme
et al., 2007). In this dataset, APOBEC3G H186R and Q275E variants
are at their highest frequency in African individuals (MAF 37% and
15%, respectively), compared to lower frequencies (MAFo10% or
o5%, respectively) in other populations (Table 1). APOBEC3G
H186R has been shown to restrict HIV-1Δvif and be sensitive to
HIV-1 Vif (An et al., 2004), but APOBEC3G Q275E has not beendescribed functionally. As these SNVs are in linkage equilibrium
(r2o0.01), we introduced these mutations into separate plasmids
containing epitope-tagged APOBEC3G. When transfected into
293T cells, APOBEC3G H186R and APOBEC3G Q275E had similar
protein expression levels as compared to wild-type APOBEC3G
(Fig. 2D, upper panel). We assayed the anti-HIV activity of the
H186R and Q275E mutants compared to wild-type APOBEC3G and
found that all APOBEC3G variants restricted HIV-1Δvif infectivity
to similar levels in a dose-dependent manner (Fig. 2D, lower panel,
solid lines). APOBEC3G H186R and APOBEC3G Q275E were also
highly sensitive to HIV-1 Vif, as infectivity was recovered to 90–
100% in the presence of Vif at all concentrations of APOBEC3G
(Fig. 2D, lower panel, dashed lines). Furthermore, we tested the
ability of APOBEC3G Q275E to restrict Alu elements. We found that
APOBEC3G Q275E restricted Alu elements similarly to wild-type
APOBEC3G (Fig. 2D, middle panel). These data suggest that
variants of APOBEC3G do not have altered antiviral activity
against HIV or Alu. Thus, we have found that common SNVs in
APOBEC3A, APOBEC3C, APOBEC3F, and APOBEC3G do not drasti-
cally affect their antiviral or anti-retrolement activities.Two polymorphisms in APOBEC3D decrease antiviral activity
Human APOBEC3D has weak antiviral activity against HIV-1 in
the absence of Vif, is highly sensitive to degradation by HIV-1 Vif,
and has strong anti-retroelement activity against Alu elements
(Dang et al., 2006; Duggal et al., 2011; Tan et al., 2009). We wanted
to identify SNVs of APOBEC3D in human populations to determine
whether any individuals have an APOBEC3D allele with stronger
anti-HIV activity. In the 1000 Genome Project dataset, we found
that the most common non-synonymous SNVs in APOBEC3D were
an arginine to cysteine change at position 97 (R97C) and an
arginine to lysine change at position 248 (R248K), which exist at
1.3% and 3.1% frequencies, respectively, in the combined human
populations. These non-synonymous SNVs are found almost
exclusively in individuals with African ancestry at low frequencies
(MAF 4.7% and 11.6%).
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Fig. 2. Common variants in APOBEC3A, C, F, and G do not affect antiviral or anti-retroelement activity. The activity of APOBEC3 mutants against HIV-1, Alu, or LINE-1
elements was compared to the activity of wild-type APOBEC3. Infectivity and retrotransposition are represented as a percentage of virus infectivity or retrotransposon
activity in the absence of APOBEC3, which was normalized to 100%. Infections were performed with dilutions of APOBEC3, and APOBEC3 levels are increasing from left to
right. Cellular APOBEC3 protein was detected byWestern blot using an anti-HA antibody, and actin was used as a loading control. (A) APOBEC3A T19A. (Upper panel) Western
blot analysis of cellular APOBEC3A (A3A) protein levels. (Lower panel) LINE-1 retrotransposition. Filled circles are wild-type APOBEC3A, and open circles are APOBEC3A T19A.
(B) APOBEC3C S1881. (Upper panel) Western blot analysis of cellular APOBEC3C (A3C) protein levels. (Lower panel) LINE-1 retrotransposition. Filled circles are wild-type
APOBEC3C, and open circles are APOBEC3C S188I. (C) APOBEC3F S108A/I231V. (Upper panel) Western blot analysis of cellular APOBEC3F (A3F) protein levels. (Middle panel)
HIV-1 infectivity. Filled circles are wild-type APOBEC3F, and open circles are APOBEC3F S108A/I231V. Dashed lines are infections with HIV-1 containing Vif (HIV-1 WT), and
solid lines are infections with HIV-1 lacking Vif (HIV-1Δvif). (Lower panel) LINE-1 retrotransposition. (D) APOBEC3G Q275E and APOBEC3G H186R. (Upper panel) Western
blot analysis of cellular APOBEC3G (A3G) protein levels. (Middle panel) Alu retrotransposition. (Lower panel) HIV-1 infectivity. Filled circles are wild-type APOBEC3G, open
circles are APOBEC3G Q275E, and gray circles are APOBEC3G H186R. Dashed lines are infections with HIV-1 containing Vif (HIV-1 WT), and solid lines are infections with
HIV-1 lacking Vif (HIV-1Δvif). Experiments were performed at least three times, and results from a representative experiment are shown. Error bars represent the standard
deviation of experimental triplicates.
N.K. Duggal et al. / Virology 443 (2013) 329–337332As these novel SNVs in APOBEC3D are in linkage equilibrium
(r2o0.01), we introduced the R97C and R248K mutations into
separate plasmids containing epitope-tagged APOBEC3D. Theseplasmids were transfected into 293T cells at multiple concentra-
tions, and we compared wild-type and mutant APOBEC3D for
protein expression by Western blot. We found that APOBEC3D
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circles. Transfections were performed with 3-fold dilutions of APOBEC3D, and APOBEC3D levels are increasing from left to right. (C) HIV-1 infectivity. Open bars are
infections with HIV-1 lacking Vif (HIV-1Δvif), ﬁlled bars are infections with HIV-1 containing Vif (HIV-1 WT), and gray bars are infections with HIV-1 lacking Vif but
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were calculated across experiments using a paired Student's t test.
N.K. Duggal et al. / Virology 443 (2013) 329–337 333R97C has similar protein levels as wild-type APOBEC3D, while
APOBEC3D R248K has drastically lower (approximately 9-fold)
protein expression than wild-type APOBEC3D (Fig. 3A). We next
assessed the two APOBEC3D mutants for antiviral activity in a
single-round HIV-1 infectivity assay. APOBEC3D R97C and APO-
BEC3D R248K restricted HIV-1Δvif by only 5- and 2-fold, which
was signiﬁcantly lower than wild-type APOBEC3D, which
restricted HIV-1Δvif by nearly 30-fold (po0.05, Fig. 3C, ﬁlled
bars). The decreased antiviral activity of APOBEC3D R97C and
APOBEC3D R248K was observed at all APOBEC3 concentrations
tested (Fig. 3B). Similarly to wild-type APOBEC3D, APOBEC3D R97C
and APOBEC3D R248K were highly sensitive to HIV-1 Vif, as
infectivity was rescued to 100% in the presence of HIV-1 Vif, and
were partially sensitive to HIV-2 Vif, as infectivity was rescued to
20–40% in the presence of HIV-2 Vif (Fig. 3C, open and gray bars).
APOBEC3G was used as a control for Vif sensitivity, as infectivity
was rescued to nearly 100% by Vif from HIV-1 and HIV-2. Thus,
variants of APOBEC3D have signiﬁcantly decreased antiviral activ-
ity against HIV-1 but similar sensitivities to Vif.
While the R97C and R248K variants of APOBEC3D are independent
mutations, they have the same functional effect of reducing the anti-
HIV potential of APOBEC3D. By determining the combined frequency
of alleles containing either the R97C or the R248K mutation, we ﬁnd
that 3.4% of APOBEC3D alleles in humans are deleterious with regards
to blocking HIV replication. Within individuals of African ancestry,
16.2% of APOBEC3D alleles are deleterious (Fig. 3D), and 4.5% of
individuals with African ancestry have two deleterious APOBEC3Dalleles. Importantly, we did not ﬁnd any common (MAF 41%)
polymorphisms in human APOBEC3D with increased antiviral activity
relative to the wild-type allele. Therefore, we conclude that the
previously reported reduced antiviral activity of human APOBEC3D
relative to chimpanzee APOBEC3D (Duggal et al., 2011) is not a
reﬂection of ascertainment bias. In fact, common variants of APO-
BEC3D in human populations are less effective at restricting HIV-1
than wild-type APOBEC3D.
Genetic separation of APOBEC3D antiviral activities
While the antiviral activity of APOBEC3D against HIV-1 is
moderate, APOBEC3D restricts Alu elements potently. To test
whether the polymorphisms in APOBEC3D affect anti-Alu activity
of APOBEC3D, we compared the anti-Alu activity of wild-type
APOBEC3D to the anti-Alu activity of APOBEC3D carrying the R97C
or R248K mutation. Interestingly, while the R97C and R248K
mutations both decreased APOBEC3D antiviral activity against
HIV-1Δvif, only the R248K mutation decreased APOBEC3D anti-
viral activity against Alu elements. At every dilution, APOBEC3D
R248K (Fig. 4, gray circles) had 4- to 5-fold lower anti-Alu activity
than wild-type APOBEC3D, where as APOBEC3D R97C (Fig. 4, open
circles) restricted Alu similarly to wild-type APOBEC3D. These data
suggest that the R248K mutation in APOBEC3D causes a global
decrease in activity, likely due to its low protein expression,
whereas the R97C mutation decreases HIV-1, but not Alu, restric-
tion. Thus, the mechanism of human APOBEC3D viral restriction
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Fig. 4. Effect of SNVs on APOBEC3D restriction of Alu elements. The antiviral activity
of APOBEC3D R97C and R248K mutants against Alu elements was compared to the
antiviral activity of wild-type APOBEC3D. Retrotransposition is represented as a
percentage of Alu activity in the absence of APOBEC3D (A3D), which was normalized
to 100%. Wild-type APOBEC3D is represented by ﬁlled circles, APOBEC3D R97C is
represented by open circles, and APOBEC3D R248K is represented by gray circles. Assays
were performed with 2-fold dilutions of APOBEC3D, and APOBEC3D levels are
increasing from left to right. Experiments were performed at least three times, and
results from a representative experiment are shown.
Table 2
Neutrality test statistics for APOBEC3 genes.
Sa πb Divergencec Tajima’s
D
Fay and
Wu’s H
HKA
χ2 d
APOBEC3A African 7 1.910−3 0.013 0.19 −3.6 0.20
597 nt Asian 5 1.910−3 0.013 0.92 −1.29 0.58
European 5 1.110−3 0.013 −0.06 −2.44 0.53
Combined 8 1.610−3 0.013 −0.05 −3.80 0.01
APOBEC3C African 1 3.010−4 0.0089 0.15 0.15 0.87
570 nt Asian 2 2.010−5 0.0087 −1.13 −1.97 0.54
European 1 1.010−5 0.0087 −0.83 0.00 0.16
Combined 4 1.010−4 0.0088 −1.24 −1.94 0.06
APOBEC3D African 7 3.010−4 0.036 −1.27 0.31 2.40
1159 nt Asian 3 2.010−5 0.036 −1.34 0.02 2.87#
European 4 1.010−5 0.036 −1.47 −1.98 2.87#
Combined 13 1.010−4 0.036 −1.89 −1.89 4.31n
APOBEC3F African 10 1.410−3 0.016 0.15 0.71 0.01
1119 nt Asian 7 1.210−3 0.016 0.55 −3.71 0.16
European 7 1.410−3 0.017 1.08 0.20 0.77
Combined 14 1.510−3 0.017 −0.13 −1.97 0.24
APOBEC3G African 9 8.410−4 0.017 −0.55 0.64 0.60
1152 nt Asian 5 5.010−4 0.017 −0.34 0.45 0.19
European 3 5.510−4 0.017 0.74 0.25 0.06
Combined 11 7.010−4 0.017 −0.79 0.62 0.23
APOBEC3H African 11 2.710−3 0.020 −0.18 −1.61 0.78
549 nt Asian 8 4.510−3 0.021 2.24n −0.74 0.46
European 6 5.310−3 0.021 4.39n 0.15 0.01
Combined 11 5.110−3 0.021 2.11 0.28 0.48
n po0.05.
# po0.10.
a S¼Number of segregating sites.
b π¼Nucleotide diversity.
c Divergence¼Human–chimpanzee divergence.
d HKA¼Hudson Kreitman Aguade test, silent sites only.
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tion by a mutation at position 97.
Molecular evolution of the APOBEC3 locus in human populations
The presence of common loss-of-function polymorphisms in
APOBEC3D, APOBEC3F, APOBEC3H, and APOBEC3B in human
populations is indicative of recent changes in demographic history
or selective pressures acting on the APOBEC3 locus. By comparing
the ratio of the rate of non-synonymous mutation (dN) to the rate
of synonymous mutations (dS), previous studies have shown
APOBEC3D, APOBEC3G, and APOBEC3H to be evolving under
recurrent ancient positive selection in primates (Duggal et al.,
2011; OhAinle et al., 2008; Sawyer et al., 2004). To determine
whether the evolution of the APOBEC3 locus has changed in recent
human history, we calculated the interspecies divergence and
intraspecies nucleotide diversity of APOBEC3A, C, DE, F, G, and H
for each human population (African, Asian, and European ances-
tries). We did not evaluate APOBEC3B because its copy number is
highly variable in humans. We found that nucleotide diversity (π)
varies between APOBEC3 genes and across each gene, but diversity
is similar between populations. The APOBEC3 genes with the
lowest average nucleotide diversity are APOBEC3C and APOBEC3D
(Table 2). Using the Hudson Kreitman Aguade (HKA) test, we
compared the polymorphic and ﬁxed changes in APOBEC3 genes
to the polymorphic and ﬁxed changes in a non-coding (putatively
neutral) region within the APOBEC3 locus. We found the nucleo-
tide diversity in APOBEC3D in humans to be signiﬁcantly lower
than expected under neutrality (HKA χ2¼4.31, po0.05, Table 2).
The trend is similar within each human population (African, Asian,
European), suggesting that this is not a population-speciﬁc event
(Table 2). This test is indicative of selective or demographic events
acting on APOBEC3D to reduce diversity.
To determine whether a selective sweep has reduced the diversity
across the APOBEC3D genomic locus in each population, we calculated
the polymorphism and divergence across APOBEC3D exons and
introns. A recent selective sweep would remove diversity across the
entire APOBEC3D locus, including introns. However, we ﬁnd that the
nucleotide diversity in APOBEC3D exons is lower than the diversity
within introns (Fig. 5, position of exons highlighted in gray). This is
suggestive of purifying selection acting on the coding regions of
APOBEC3D to reduce non-synonymous variation, rather than an
advantageous haplotype sweeping through a population.
From these population genetics analyses, we conclude that,
while APOBEC3D, APOBEC3G, and APOBEC3H have previouslybeen shown to evolve under positive selection during human–
chimpanzee divergence, it is unlikely that APOBEC3D is still
evolving under positive selection within humans. Importantly,
APOBEC3D has evolved under purifying selection in recent human
history, suggesting that a cellular function of APOBEC3D has been
optimized and conserved due to continuous selective pressure.Discussion
In this study, we characterized the level of diversity in the
APOBEC3 locus in human populations and the effects of variants
on APOBEC3 antiviral activity. We ﬁnd that high frequency SNVs in
APOBEC3A, C, F, and G genes do not affect antiviral activity.
However, we found that two common variants in APOBEC3D
(R97C and R248K), which are limited to African populations,
decrease the antiviral activity of APOBEC3D against HIV-1, and
one variant (R248K) also decreases anti-Alu activity. Further, we
show that the pattern of diversity in the APOBEC3D is indicative of
recent purifying selection in humans. Together, these data indicate
that APOBEC3D plays an important role in host defense in humans.
Because the R248K mutation likely has decreased anti-Alu activity
due to its low protein expression (Fig. 4), its deleterious effects may be
compensated in vivo by another polymorphism that was not included
in the plasmid used for transfection. For example, the R248K poly-
morphism is in tight linkage disequlibrium (r240.8) with two
additional polymorphisms in non-coding regions near APOBEC3D that
may compensate for the low in vitro expression level. It is also possible
that the R248K polymorphism is only slightly deleterious and that the
purifying selection acting on APOBEC3D is weak. This is supported by
the relatively low frequency of the R248K polymorphism in the
human population. Either way, we conclude that APOBEC3D is subject
to purifying selection, and the anti-Alu function of APOBEC3D is
conserved in most individuals. Thus, we suggest that anti-Alu activity
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Fig. 5. Diversity across APOBEC3D within human populations. Sliding window analysis of diversity across intronic and exonic regions of APOBEC3D, stratiﬁed by population.
Heterozygosity (π) is plotted for each population. Green represents individuals of African ancestry, purple represents individuals of Asian ancestry, and orange represents
individuals of European ancestry. Positions of exons are highlighted in gray. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
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APOBEC3D in humans. Because APOBEC3D has rapidly evolved in
chimpanzees yet has not altered anti-Alu activity (Duggal et al., 2011),
it is likely that this function is subject to purifying selection in
chimpanzees as well. However, in the absence of an additional
selective pressure, purifying selection is the main evolutionary force
affecting APOBEC3D in humans. This is supported by previous studies
showing that APOBEC3D mRNA is expressed in human embryonic
stem cells (Wissing et al., 2011), the cell type where Alu elements can
have the most deleterious effect on a population. In addition, because
endogenous mobile elements do not trigger an interferon response, it
is interesting that APOBEC3D mRNA is constitutively expressed with
only moderate upregulation by interferon.
The observation of recent purifying selection in APOBEC3D
(Fig. 5 and Table 2) is in contrast to the ancient adaptive evolution
that has been implicated for many APOBEC3 family members. The
arms race between restriction factors and retroviruses is generally
thought to induce rapid evolution in immune-related genes and
viruses (Duggal and Emerman, 2012). However, recent purifying
selection suggests that the antiviral activity of the human reper-
toire of APOBEC3 genes was optimized against a selective pressure,
and this antiviral activity has been maintained. While APOBEC3
restriction factors have an important role in host defense in
humans, the consequences of purifying selective pressure are that
some APOBEC3 genes, such as APOBEC3D, are not optimized to
restrict the lentiviruses circulating today.
Based on other studies showing that endogenous APOBEC3D,
APOBEC3F, and APOBEC3G expression decreases HIV-1 replication
in HIV target cells (Refsland et al., 2012), it is possible that the
novel variants in APOBEC3D described here may have a role in
HIV-1 acquisition or disease progression. These polymorphisms
will be very difﬁcult to associate with disease outcomes due to
their low frequency, though detecting the inﬂuence of rare genetic
variants on disease susceptibility is becoming a possibility
(Tennessen et al., 2012). On the other hand, our studies suggest
that most common variants of APOBEC3 proteins do not have
altered activity against HIV. However, this study supports investi-
gating the functional consequences of low frequency alleles in host
defense genes, and more studies evaluating the effects of muta-
tions in immune-related genes are needed to fully understand the
cumulative impact that variants could have on human health.Materials and methods
APOBEC3 genotype data
SNVs in the APOBEC3 locus (GRCh37, Chr22: 39347756–
39501072) from 913 individuals were obtained through the 1000
Genome Project May 2011 phase 1 low-coverage phased genotyperelease (www.1000genomes.org). Insertions and deletions were
obtained for 911 individuals from the 1000 Genome Project
February 2012 integrated phase 1 release. The African population
includes 61 African ancestry individuals from southwest US, 97
Luhya individuals in Webuye, Kenya, and 88 Yoruba individuals
from Ibadan, Nigeria. The Asian population includes 97 Han
Chinese individuals in Beijing, 100 Chinese individuals in Denver,
and 89 Japanese individuals in Tokyo. The European population
includes 87 individuals with European ancestry in Utah, 93 Finnish
individuals from Finland, 89 British individuals from England and
Scotland, 14 individuals from Iberian populations in Spain, and
98 Toscani in Italy. The ancestral state of each allele was deter-
mined by comparison to the chimpanzee genome.
APOBEC3 plasmids
Human APOBEC3A, APOBEC3C, APOBEC3D, and APOBEC3G
were cloned into the expression vector pCS2, and human APO-
BEC3F was cloned into the expression vector pCDNA3.1. A hemag-
glutinin (HA) tag was added to the C-terminus of all APOBEC3
proteins. Mutations were introduced into APOBEC3 plasmids using
overlapping PCR. Primer sequences are available upon request.
Cell lines, transfections, and Western blot analysis
SupT1 cells were maintained in RPMI/1% Pen/Strep/10% FBS at
37oC in a CO2 incubator. 293T, HeLa, and HeLa-HA cells were
maintained similarly in DMEM/1% Pen/Strep/10% BGS. Transfec-
tions were performed with TransIT-LT1 transfection reagent
(Mirus Bio) at a reagent:plasmid DNA ratio of 2:1. Transfected
cells and viral lysates were harvested 48 h after transfection. Cells
were lysed in NP40-doc buffer (1% NP40, 0.2% sodiumdeoxycho-
late, 0.12 M NaCl, 20 mM Tris pH 8.0, 2.4 mM DTT) with protease
inhibitors (Roche) and spun for 1 min at 16,000 g, and super-
natants were quantiﬁed by Bradford assay. Lysates were resolved
by 10% SDS-PAGE, transferred to PVDF membranes, and probed
with anti-HA (Santa Cruz Biotech) or anti-actin (Sigma).
Retrotransposition assays
LINE-1 and Alu assays were performed as described previously
(Dewannieux et al., 2003; OhAinle et al., 2008; Ribet et al., 2004;
Wei et al., 2001) with some modiﬁcations. Cells were plated in
6-well plates at 8104 cells/well, and, 24 h later, cells were
transfected. For L1 assays, 0.1 μg LINE-1 plasmid (JM101/L1.3
(Moran et al., 1999; Wei et al., 2001)) and 0.6 μg APOBEC or empty
plasmid were transfected into HeLa cells. For Alu assays, 1 μg Alu
plasmid (AluneoTET (Dewannieux et al., 2003) or Alu-Ya5-eab
(Bennett et al., 2008)), 0.3 μg Orf2p (pCep5′UTRORF2Δneo (Alisch
et al., 2006)), and 0.45 μg APOBEC or empty plasmid were
N.K. Duggal et al. / Virology 443 (2013) 329–337336transfected into HeLa-HA cells. Three days after transfection, cells
were selected in G418 for 10–12 days. Colonies were stained with
crystal violet and counted manually.
Viral infectivity assays
Single-round HIV-1 infectivity assays were performed as
described (Yamashita and Emerman, 2004). To produce VSV-G-
pseudotyped HIV-1, 3106 293T cells were plated in a 6-well
plate, and 24 h later, co-transfected with 0.6 μg lentiviral vector
(pLai3ΔenvLuc2 (Yamashita and Emerman, 2004), pLai3Δenv-
Luc2Δvif (OhAinle et al., 2006), 0.2 μg L-VSV-G, and 0.2 μg APOBEC
or empty plasmid. HIV-1 expressing Vif from HIV-2 was made
using pLai3ΔenvLuc2ΔvifLk/vifROD9 (Li et al., 2010). Virus was
harvested 48 h after transfection and ﬁltered through a 0.2 μm
ﬁlter. Virus was quantiﬁed by p24 gag ELISA (Advanced
BioScience), and virus equivalent to two nanograms of p24 gag
was used to infect 4104 SupT1 cells in a 96-well plate in the
presence of 20 ug/mL DEAE-dextran. Forty-eight hours after
transfection, cells from triplicate infections were lysed in Bright-
Glo Luciferase Assay Reagent (Promega) and read on a lumin-
ometer. Error bars are the standard deviation of experimental
triplicates. p-values were calculated using a two-tailed Student’s
t-test.
Population genetics analyses
Population genetics calculations were performed using DnaSP
v5 (Librado and Rozas, 2009). The HKA test was performed using
by comparing APOBEC3 genes to a 2 kb noncoding region of the
APOBEC3 locus (Chr. 22: 39403000–39405000). Signiﬁcance of the
HKA test was determined using the χ2 value with 11 of freedom.
Signiﬁcance of Tajima’s D and Fay and Wu’s H tests were deter-
mined using 10,000 coalescent simulations based on the observed
θ with no recombination. The outgroup used for all tests was the
UCSC chimpanzee sequence, accessed through the SeattleSeq
Annotation 134 webserver. Sliding windows were calculated with
a window size of 100 nucleotides and an overlap of 25 nucleotides.
Linkage disequilibrium (r2) was calculated using Haploview v4.2
(Barrett et al., 2005).Acknowledgments
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